-inc-logo-1200x675.jpg?v=20240515130629)
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Get Free Report) CAO Carrie Liao sold 2,347 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total transaction of $15,818.78. Following the completion of the sale, the chief accounting officer now owns 144,923 shares of the company's stock, valued at approximately $976,781.02. The trade was a 1.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Carrie Liao also recently made the following trade(s):
- On Thursday, December 26th, Carrie Liao sold 2,273 shares of Mind Medicine (MindMed) stock. The stock was sold at an average price of $7.43, for a total transaction of $16,888.39.
Mind Medicine (MindMed) Stock Down 2.9 %
Shares of NASDAQ MNMD opened at $6.58 on Thursday. The firm has a fifty day simple moving average of $7.28 and a two-hundred day simple moving average of $6.96. The firm has a market capitalization of $495.92 million, a PE ratio of -2.91 and a beta of 2.57. The company has a current ratio of 9.00, a quick ratio of 9.00 and a debt-to-equity ratio of 0.09. Mind Medicine has a 12 month low of $5.03 and a 12 month high of $12.22.
Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.08). During the same period in the prior year, the company earned ($0.59) EPS. Equities analysts expect that Mind Medicine will post -1.35 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Barclays PLC raised its holdings in Mind Medicine (MindMed) by 203.6% in the third quarter. Barclays PLC now owns 136,098 shares of the company's stock worth $775,000 after purchasing an additional 91,271 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Mind Medicine (MindMed) by 142.6% in the 3rd quarter. Wellington Management Group LLP now owns 185,722 shares of the company's stock worth $1,057,000 after buying an additional 109,152 shares during the period. Geode Capital Management LLC increased its stake in shares of Mind Medicine (MindMed) by 10.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,677,702 shares of the company's stock worth $9,548,000 after acquiring an additional 162,933 shares in the last quarter. SG Americas Securities LLC lifted its position in Mind Medicine (MindMed) by 48.8% during the 4th quarter. SG Americas Securities LLC now owns 24,406 shares of the company's stock valued at $170,000 after acquiring an additional 8,004 shares during the period. Finally, State Street Corp increased its stake in shares of Mind Medicine (MindMed) by 0.5% during the third quarter. State Street Corp now owns 1,814,829 shares of the company's stock valued at $10,326,000 after purchasing an additional 9,782 shares in the last quarter. Hedge funds and other institutional investors own 27.91% of the company's stock.
Analyst Ratings Changes
Several analysts have issued reports on MNMD shares. Robert W. Baird cut their price target on shares of Mind Medicine (MindMed) from $27.00 to $16.00 and set an "outperform" rating for the company in a research report on Friday, March 7th. Chardan Capital initiated coverage on Mind Medicine (MindMed) in a research report on Friday, December 20th. They set a "buy" rating and a $20.00 price target on the stock. Evercore ISI began coverage on Mind Medicine (MindMed) in a research report on Tuesday, January 28th. They issued an "outperform" rating and a $23.00 price objective for the company. Oppenheimer restated an "outperform" rating and issued a $20.00 target price on shares of Mind Medicine (MindMed) in a report on Tuesday, December 17th. Finally, HC Wainwright reiterated a "buy" rating and set a $55.00 price target on shares of Mind Medicine (MindMed) in a report on Friday, March 7th. Ten analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $25.11.
Get Our Latest Stock Report on Mind Medicine (MindMed)
About Mind Medicine (MindMed)
(
Get Free Report)
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
